p.84 抽出テキスト
376. Veve MP, McCurry ED, Cooksey GE, Shorman MA. Epidemiology and outcomes of non-HACEK infective endocarditis in the southeast United States. PLoS One 2020; 15:e0230199. https://doi.org/10.1371/journal.pone.0230199 377. Tattevin P, Watt G, Revest M, Arvieux C, Fournier PE. Update on blood culturenegative endocarditis. Med Mal Infect 2015;45:1–8. https://doi.org/10.1016/j.medmal. 2014.11.003 378. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore) 2005;84:162–173. https://doi.org/10. 1097/01.md.0000165658.82869.17 379. Raoult D, Fournier PE, Vandenesch F, Mainardi JL, Eykyn SJ, Nash J, et al. Outcome and treatment of Bartonella endocarditis. Arch Intern Med 2003;163:226–230. https://doi. org/10.1001/archinte.163.2.226 380. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation 1997;96:358–366. https://doi.org/10.1161/01.CIR.96.1.358 381. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004;48:1921–33. https://doi.org/10.1128/AAC.48.6.1921-1933.2004 382. Ghigo E, Capo C, Aurouze M, Tung CH, Gorvel JP, Raoult D, et al. Survival of Tropheryma whipplei, the agent of Whipple’s disease, requires phagosome acidification. Infect Immun 2002;70:1501–1506. https://doi.org/10.1128/IAI.70.3.1501-1506.2002 383. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 2001;14:177–207. https://doi.org/10.1128/CMR.14.1.177-207.2001 384. Garcia-Alvarez L, Sanz MM, Marin M, Farinas MC, Montejo M, Goikoetxea J, et al. Antimicrobial management of Tropheryma whipplei endocarditis: the Spanish collaboration on endocarditis (games) experience. J Antimicrob Chemother 2019;74: 1713–1717. https://doi.org/10.1093/jac/dkz059 385. Calderon Parra J, De Castro-Campos D, Munoz Garcia P, Olmedo Samperio M, Marin Arriaza M, De Alarcon A, et al. Non-HACEK Gram negative bacilli endocarditis: analysis of a national prospective cohort. Eur J Intern Med 2021;92:71–78. https://doi.org/ 10.1016/j.ejim.2021.04.021 386. Tattevin P, Revest M, Lefort A, Michelet C, Lortholary O. Fungal endocarditis: current challenges. Int J Antimicrob Agents 2014;44:290–294. https://doi.org/10.1016/j. ijantimicag.2014.07.003 387. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine (Baltimore) 2011;90:237–249. https://doi.org/10.1097/ MD.0b013e3182259d38 388. Kalokhe AS, Rouphael N, El Chami MF, Workowski KA, Ganesh G, Jacob JT. Aspergillus endocarditis: a review of the literature. Int J Infect Dis 2010;14:e1040–e1047. https://doi.org/10.1016/j.ijid.2010.08.005 389. Lye DC, Hughes A, O’Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis 2005;24:753–755. https://doi.org/10. 1007/s10096-005-0038-2 390. Valerio M, Camici M, Machado M, Galar A, Olmedo M, Sousa D, et al. Aspergillus endocarditis in the recent years, report of cases of a multicentric national cohort and literature review. Mycoses 2022;65:362–373. https://doi.org/10.1111/myc.13415 391. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 2007;45:3546–3548. https://doi.org/10.1128/JCM.01555-07 392. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011;17:1581–1586. https:// doi.org/10.1111/j.1469-0691.2010.03425.x 393. Braquet P, Alla F, Cornu C, Goehringer F, Piroth L, Chirouze C, et al. Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study. Clin Microbiol Infect 2016;22:948.e1–948.e7. https://doi.org/10.1016/j. cmi.2016.07.034 394. Willekens R, Puig-Asensio M, Suanzes P, Fernandez-Hidalgo N, Larrosa MN, Gonzalez-Lopez JJ, et al. Empirical use of beta-lactam/beta-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study. J Antimicrob Chemother 2022;77:2288–2295. https://doi.org/10.1093/jac/ dkac152 395. VanEperen AS, Segreti J. Empirical therapy in methicillin-resistant Staphylococcus aureus infections: an up-to-date approach. J Infect Chemother 2016;22:351–359. https://doi. org/10.1016/j.jiac.2016.02.012 396. Rezar R, Jirak P, Lichtenauer M, Jung C, Lauten A, Hoppe UC, et al. Partial oral antibiotic therapy is non-inferior to intravenous therapy in non-critically ill patients with infective endocarditis: review and meta-analysis. Wien Klin Wochenschr 2020;132:762–769. https://doi.org/10.1007/s00508-020-01614-z 397. Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review. JAMA Intern Med 2020;180:769–777. https:// doi.org/10.1001/jamainternmed.2020.0555 398. Rajaratnam D, Rajaratnam R. Outpatient antimicrobial therapy for infective endocarditis is safe. Heart Lung Circ 2021;30:207–215. https://doi.org/10.1016/j.hlc.2020.08. 016 399. Perica SJ, Llopis J, Gonzalez-Ramallo V, Goenaga MA, Munoz P, Garcia-Leoni ME, et al. Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the games cohort. Clin Infect Dis 2019;69:1690–1700. https://doi.org/ 10.1093/cid/ciz030 400. Forestier E, Roubaud-Baudron C, Fraisse T, Patry C, Gavazzi G, Hoen B, et al. Comprehensive geriatric assessment in older patients suffering from infective endocarditis. A prospective multicentric cohort study. Clin Microbiol Infect 2019;25: 1246–1252. https://doi.org/10.1016/j.cmi.2019.04.021 401. Pries-Heje MM, Wiingaard C, Ihlemann N, Gill SU, Bruun NE, Elming H, et al. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. N Engl J Med 2022; 386:601–602. https://doi.org/10.1056/NEJMc2114046 402. Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis 2018;67: 795–798. https://doi.org/10.1093/cid/ciy279 403. Iung B, Doco-Lecompte T, Chocron S, Strady C, Delahaye F, Le Moing V, et al. Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices. Eur Heart J 2016;37: 840–848. https://doi.org/10.1093/eurheartj/ehv650 404. Ostergaard L, Oestergaard LB, Lauridsen TK, Dahl A, Chaudry M, Gislason G, et al. Long-term causes of death in patients with infective endocarditis who undergo medical therapy only or surgical treatment: a nationwide population-based study. Eur J Cardiothorac Surg 2018;54:860–866. https://doi.org/10.1093/ejcts/ezy156 405. Arminanzas C, Farinas-Alvarez C, Zarauza J, Munoz P, Gonzalez Ramallo V, Martinez Selles M, et al. Role of age and comorbidities in mortality of patients with infective endocarditis. Eur J Intern Med 2019;64:63–71. https://doi.org/10.1016/j.ejim.2019.03. 006 406. Diab M, Sponholz C, von Loeffelholz C, Scheffel P, Bauer M, Kortgen A, et al. Impact of perioperative liver dysfunction on in-hospital mortality and long-term survival in infective endocarditis patients. Infection 2017;45:857–866. https://doi.org/10.1007/s15010- 017-1064-6 407. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012;41:734–744, discussion 744–745. https://doi.org/10.1093/ejcts/ezs043 408. Shahian DM, Jacobs JP, Badhwar V, Kurlansky PA, Furnary AP, Cleveland JC Jr, et al. The Society of Thoracic Surgeons 2018 adult cardiac surgery risk models: Part 1-background, design considerations, and model development. Ann Thorac Surg 2018;105: 1411–1418. https://doi.org/10.1016/j.athoracsur.2018.03.002 409. Costa MA, Wollmann DR Jr, Campos AC, Cunha CL, Carvalho RG, Andrade DF, et al. Risk index for death by infective endocarditis: a multivariate logistic model. Rev Bras Cir Cardiovasc 2007;22:192–200. https://doi.org/10.1590/s0102-76382007000200007 410. De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. Sci World J 2012;2012:307571. https://doi.org/10.1100/2012/307571 411. Di Mauro M, Dato GMA, Barili F, Gelsomino S, Sante P, Corte AD, et al. A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The endoscore. Int J Cardiol 2017;241:97–102. https://doi.org/10.1016/j. ijcard.2017.03.148 412. Fernandez-Hidalgo N, Ferreria-Gonzalez I, Marsal JR, Ribera A, Aznar ML, de Alarcon A, et al. A pragmatic approach for mortality prediction after surgery in infective endocarditis: optimizing and refining EuroSCORE. Clin Microbiol Infect 2018;24:1102.e7–- 1102.e15. https://doi.org/10.1016/j.cmi.2018.01.019 413. Gaca JG, Sheng S, Daneshmand MA, O’Brien S, Rankin JS, Brennan JM, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg 2011;141:98–106.e2. https://doi.org/10.1016/j.jtcvs.2010.09.016 414. Gatti G, Perrotti A, Obadia JF, Duval X, Iung B, Alla F, et al. Simple scoring system to predict in-hospital mortality after surgery for infective endocarditis. J Am Heart Assoc 2017;6:e004806. https://doi.org/10.1161/JAHA.116.004806 415. Chu VH, Park LP, Athan E, Delahaye F, Freiberger T, Lamas C, et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Circulation 2015;131:131–140. https://doi.org/10.1161/CIRCULATIONAHA.114.012461 416. Varela Barca L, Fernandez-Felix BM, Navas Elorza E, Mestres CA, Munoz P, Cuerpo-Caballero G, et al. Prognostic assessment of valvular surgery in active infective endocarditis: multicentric nationwide validation of a new score developed from a meta-analysis. Eur J Cardiothorac Surg 2020;57:724–731. https://doi.org/10.1093/ejcts/ ezz328 417. Varela Barca L, Navas Elorza E, Fernandez-Hidalgo N, Moya Mur JL, Muriel Garcia A, Fernandez-Felix BM, et al. Prognostic factors of mortality after surgery in infective endocarditis: systematic review and meta-analysis. Infection 2019;47:879–895. https://doi.org/10.1007/s15010-019-01338-x 418. Fernandez-Cisneros A, Hernandez-Meneses M, Llopis J, Sandoval E, Pereda D, Alcocer J, et al. Risk scores’ performance and their impact on operative decision-making in left- ESC Guidelines 4031 Downloaded from academic.oup.com/eurheartj/article/44/39/3948/7243107 by guest on 07 October 2026